397 related articles for article (PubMed ID: 11744804)
1. Methylenetetrahydrofolate reductase gene polymorphism, hyperhomocysteinemia, and cardiovascular diseases in chronic hemodialysis patients.
Morimoto K; Haneda T; Okamoto K; Ishida H; Kikuchi K
Nephron; 2002 Jan; 90(1):43-50. PubMed ID: 11744804
[TBL] [Abstract][Full Text] [Related]
2. Influence of 5,10-methylenetetrahydrofolate reductase gene polymorphism on plasma homocysteine concentration in patients with end-stage renal disease.
Lee HA; Choi JS; Ha KS; Yang DH; Chang SK; Hong SY
Am J Kidney Dis; 1999 Aug; 34(2):259-63. PubMed ID: 10430972
[TBL] [Abstract][Full Text] [Related]
3. Methylenetetrahydrofolate reductase genotype, vitamin B12, and folate influence plasma homocysteine in hemodialysis patients.
Nakamura T; Saionji K; Hiejima Y; Hirayama H; Tago K; Takano H; Tajiri M; Hayashi K; Kawabata M; Funamizu M; Makita Y; Hata A
Am J Kidney Dis; 2002 May; 39(5):1032-9. PubMed ID: 11979347
[TBL] [Abstract][Full Text] [Related]
4. The common mutations C677T and A1298C in the human methylenetetrahydrofolate reductase gene are associated with hyperhomocysteinemia and cardiovascular disease in hemodialysis patients.
Haviv YS; Shpichinetsky V; Goldschmidt N; Atta IA; Ben-Yehuda A; Friedman G
Nephron; 2002 Sep; 92(1):120-6. PubMed ID: 12187094
[TBL] [Abstract][Full Text] [Related]
5. Hyperhomocysteinemia is related to residual glomerular filtration and folate, but not to methylenetetrahydrofolate-reductase and methionine synthase polymorphisms, in supplemented end-stage renal disease patients undergoing hemodialysis.
Anwar W; Guéant JL; Abdelmouttaleb I; Adjalla C; Gérard P; Lemoel G; Erraess N; Moutabarrek A; Namour F
Clin Chem Lab Med; 2001 Aug; 39(8):747-52. PubMed ID: 11592445
[TBL] [Abstract][Full Text] [Related]
6. Effect of MTHFR 677C>T on plasma total homocysteine levels in renal graft recipients.
Födinger M; Wölfl G; Fischer G; Rasoul-Rockenschaub S; Schmid R; Hörl WH; Sunder-Plassmann G
Kidney Int; 1999 Mar; 55(3):1072-80. PubMed ID: 10027946
[TBL] [Abstract][Full Text] [Related]
7. The role of vitamin B12 in fasting hyperhomocysteinemia and its interaction with the homozygous C677T mutation of the methylenetetrahydrofolate reductase (MTHFR) gene. A case-control study of patients with early-onset thrombotic events.
D'Angelo A; Coppola A; Madonna P; Fermo I; Pagano A; Mazzola G; Galli L; Cerbone AM
Thromb Haemost; 2000 Apr; 83(4):563-70. PubMed ID: 10780318
[TBL] [Abstract][Full Text] [Related]
8. Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients.
Födinger M; Mannhalter C; Wölfl G; Pabinger I; Müller E; Schmid R; Hörl WH; Sunder-Plassmann G
Kidney Int; 1997 Aug; 52(2):517-23. PubMed ID: 9264011
[TBL] [Abstract][Full Text] [Related]
9. Polymorphism in methylenetetrahydrofolate reductase gene: its impact on plasma homocysteine levels and carotid atherosclerosis in ESRD patients receiving hemodialysis.
Lim PS; Hung WR; Wei YH
Nephron; 2001 Mar; 87(3):249-56. PubMed ID: 11287760
[TBL] [Abstract][Full Text] [Related]
10. Association of two MTHFR polymorphisms with total homocysteine plasma levels in dialysis patients.
Födinger M; Buchmayer H; Heinz G; Papagiannopoulos M; Kletzmayr J; Perschl A; Vychytil A; Hörl WH; Sunder-Plassmann G
Am J Kidney Dis; 2001 Jul; 38(1):77-84. PubMed ID: 11431185
[TBL] [Abstract][Full Text] [Related]
11. [Frequency of hyperhomocysteinemia in hemodialysis patients with folic acid supplementation].
Kárpáti I; Balla J; Szóke G; Bereczky Z; Páll D; Ben T; Toma K; Katona E; Mohácsi A; Paragh G; Varga Z; Kakuk G; Muszbek L
Orv Hetil; 2002 Jul; 143(27):1635-40. PubMed ID: 12180000
[TBL] [Abstract][Full Text] [Related]
12. An MTHFR variant, homocysteine, and cardiovascular comorbidity in renal disease.
Wrone EM; Zehnder JL; Hornberger JM; McCann LM; Coplon NS; Fortmann SP
Kidney Int; 2001 Sep; 60(3):1106-13. PubMed ID: 11532106
[TBL] [Abstract][Full Text] [Related]
13. Methylenetetrahydrofolate reductase gene mutation and hyperhomocysteinemia as a risk factor for coronary heart disease in the Indian population.
Nair KG; Nair SR; Ashavaid TF; Dalal JJ; Eghlim FF
J Assoc Physicians India; 2002 May; 50 Suppl():9-15. PubMed ID: 12186157
[TBL] [Abstract][Full Text] [Related]
14. Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients.
Bostom AG; Shemin D; Lapane KL; Nadeau MR; Sutherland P; Chan J; Rozen R; Yoburn D; Jacques PF; Selhub J; Rosenberg IH
Atherosclerosis; 1996 Jun; 123(1-2):193-202. PubMed ID: 8782850
[TBL] [Abstract][Full Text] [Related]
15. Hyperhomocysteinaemia, folate and vitamin B12 in unsupplemented haemodialysis patients: effect of oral therapy with folic acid and vitamin B12.
Billion S; Tribout B; Cadet E; Queinnec C; Rochette J; Wheatley P; Bataille P
Nephrol Dial Transplant; 2002 Mar; 17(3):455-61. PubMed ID: 11865092
[TBL] [Abstract][Full Text] [Related]
16. [Methylenetetrahydrofolate reductase gene polymorphism and plasma homocysteine levels in hemodialysing patients].
Yao Y; Liu H; Zhang X; Duan X
Zhonghua Nei Ke Za Zhi; 2002 Aug; 41(8):522-5. PubMed ID: 12421498
[TBL] [Abstract][Full Text] [Related]
17. Methylenetetrahydrofolate reductase gene C677T polymorphism, plasma homocysteine and folate in end-stage renal disease dialysis and non-dialysis patients.
Zychma MJ; Gumprecht J; Grzeszczak W; Zukowska-Szczechowska E;
Nephron; 2002 Sep; 92(1):235-9. PubMed ID: 12187113
[TBL] [Abstract][Full Text] [Related]
18. [Some aspects of homocysteine metabolism in hemodialysis patients].
Bednarek-Skublewska A; Buraczyńska M; Wawrzycki S; Baranowicz-Gaszczyk I; Ksiazek A
Pol Arch Med Wewn; 2002 Nov; 108(5):1041-7. PubMed ID: 12685244
[TBL] [Abstract][Full Text] [Related]
19. Interplay between methylenetetrahydrofolate reductase gene polymorphism 677C-->T and serum folate levels in determining hyperhomocysteinemia in heart transplant recipients.
Potena L; Grigioni F; Viggiani M; Magnani G; Sorbello S; Falchetti E; Sassi S; Mantovani V; Bacchi-Reggiani L; Magelli C; Branzi A
J Heart Lung Transplant; 2001 Dec; 20(12):1245-51. PubMed ID: 11744407
[TBL] [Abstract][Full Text] [Related]
20. Vitamin B12 decreases, but does not normalize, homocysteine and methylmalonic acid in end-stage renal disease: a link with glycine metabolism and possible explanation of hyperhomocysteinemia in end-stage renal disease.
Hyndman ME; Manns BJ; Snyder FF; Bridge PJ; Scott-Douglas NW; Fung E; Parsons HG
Metabolism; 2003 Feb; 52(2):168-72. PubMed ID: 12601627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
